Unichem Labs sizzles after securing USFDA nod

Image
Capital Market
Last Updated : Dec 12 2018 | 9:50 AM IST

Unichem Laboratories rose 2.33% to Rs 195.70 at 09:31 IST on BSE after the company received a tentative approval for its ANDA, Tadalafil tablets from USFDA.

The announcement was made after market hours yesterday, 11 December 2018.

Meanwhile, the S&P BSE Sensex was up 255.06 points, or 0.73% to 35,405.07

On the BSE, 8,981 shares were traded in the counter so far compared with average daily volumes of 11,000 shares in the past two weeks. The stock had hit a high of Rs 198.05 and a low of Rs 194.30 so far during the day. The stock hit a record high of Rs 382 on 8 January 2018. The stock hit a 52-week low of Rs 182 on 11 October 2018.

Unichem Laboratories said it has received a tentative approval for its ANDA, Tadalafil Tablets: 2.5 mg, 5 mg, 10 mg and 20 mg from the the United States food and Drug Administration for a generic version of ELI LILLY's Cialis, 2.5 mg, 5 mg, 10 mg and 20 mg. Unichem's Tadalafil tablets are indicated for the treatment of erectile dysfunction (ED) and the signs and symptoms of benign prostatic hyperplasia (BPH).

Unichem Laboratories' net profit dropped 66.8% to Rs 15.21 crore on 12.74% rise in total income to Rs 278.50 crore in Q2 September 2018 over Q2 September 2017.

Unichem Laboratories is a pharmaceutical company.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 12 2018 | 9:41 AM IST

Next Story